AJP - Regulatory, Integrative and Comparative Physiology, Vol 259, Issue 5 1025-R1034, Copyright © 1990 by American Physiological Society

ARTICLES

Role of central mineralocorticoid binding sites in development of hypertension

P. C. Janiak, S. J. Lewis and M. J. Brody
Department of Pharmacology, University of Iowa, College of Medicine, Iowa City 52242.

The possibility that central mineralocorticoid binding sites are involved in the development of mineralocorticoid hypertension was examined using chronic blockade of these sites with a specific mineralocorticoid receptor antagonist RU 28318 administered by intracerebroventricular (icv) infusion. The antagonist significantly attenuated the development of deoxycorticosterone acetate (DOCA)-salt hypertension, but the development of one-kidney, one-clip renal hypertension was not affected. This antihypertensive action was attributable to a central action, since intraperitoneal infusion of the same dose of mineralocorticoid antagonist did not alter the peak development of DOCA-salt hypertension. The icv infusion of RU 28318 did not change either the increase of fluid intake induced by DOCA-salt treatment or the pressor reactivity to centrally or peripherally injected arginine vasopressin and angiotensin II and peripherally administered phenylephrine. The antihypertensive action of icv infusion of the mineralocorticoid antagonist was associated with a reduction of neurogenic vasomotor tone and a restoration of impaired arterial baroreflexes. We conclude that functional integrity of central mineralocorticoid binding sites is required for the full development of DOCA-salt hypertension.

This article has been cited by other articles:

				B. S. Huang, H. Wang, and F. H. H. Leenen Chronic central infusion of aldosterone leads to sympathetic hyperreactivity and hypertension in Dahl S but not Dahl R rats Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H517 - H524. [Abstract] [Full Text] [PDF]

				C. Ngarmukos and R. J. Grekin Nontraditional aspects of aldosterone physiology Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1122 - E1127. [Abstract] [Full Text] [PDF]

				H. E. De Wardener The Hypothalamus and Hypertension Physiol Rev, October 1, 2001; 81(4): 1599 - 1658. [Abstract] [Full Text] [PDF]

				K. Rahmouni, M. Barthelmebs, M. Grima, J.-L. Imbs, and W. De Jong Involvement of Brain Mineralocorticoid Receptor in Salt-Enhanced Hypertension in Spontaneously Hypertensive Rats Hypertension, October 1, 2001; 38(4): 902 - 906. [Abstract] [Full Text] [PDF]

				K. Rahmouni, M. Barthelmebs, M. Grima, J.-L. Imbs, and W. De Jong Brain Mineralocorticoid Receptor Control of Blood Pressure and Kidney Function in Normotensive Rats Hypertension, May 1, 1999; 33(5): 1201 - 1206. [Abstract] [Full Text] [PDF]